Medeon Biodesign (6499) - Total Assets
Based on the latest financial reports, Medeon Biodesign (6499) holds total assets worth NT$1.42 Billion TWD (≈ $44.65 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 6499 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Medeon Biodesign - Total Assets Trend (2017–2024)
This chart illustrates how Medeon Biodesign's total assets have evolved over time, based on quarterly financial data. See Medeon Biodesign shareholders equity for net asset value and shareholders' equity analysis.
Medeon Biodesign - Asset Composition Analysis
Current Asset Composition (December 2024)
Medeon Biodesign's total assets of NT$1.42 Billion consist of 70.2% current assets and 29.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 27.3% |
| Accounts Receivable | NT$37.84 Million | 2.0% |
| Inventory | NT$34.10 Million | 1.8% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Medeon Biodesign's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Medeon Biodesign.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medeon Biodesign's current assets represent 70.2% of total assets in 2024, a decrease from 70.9% in 2017.
- Cash Position: Cash and equivalents constituted 27.3% of total assets in 2024, up from 17.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 2.0% of total assets.
Medeon Biodesign Competitors by Total Assets
Key competitors of Medeon Biodesign based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Blue Sail Medical Co Ltd
SHE:002382
|
China | CN¥16.12 Billion |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Ocumetics Technology Corp
V:OTC
|
Canada | CA$1.15 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.33 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
Trajan Group Holdings Ltd
AU:TRJ
|
Australia | AU$192.32 Million |
|
Osteopore Ltd
AU:OSX
|
Australia | AU$2.77 Million |
|
Nyxoah
BR:NYXH
|
Belgium | €93.60 Million |
Medeon Biodesign - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.03 | 9.21 | 10.22 |
| Quick Ratio | 4.89 | 9.11 | 10.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$735.50 Million | NT$1.54 Billion | NT$1.61 Billion |
Medeon Biodesign - Advanced Valuation Insights
This section examines the relationship between Medeon Biodesign's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.54 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | -31.6% |
| Total Assets | NT$1.88 Billion |
| Market Capitalization | $187.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values Medeon Biodesign's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Medeon Biodesign's assets decreased by 31.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Medeon Biodesign (2017–2024)
The table below shows the annual total assets of Medeon Biodesign from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.88 Billion ≈ $59.16 Million |
-31.65% |
| 2023-12-31 | NT$2.75 Billion ≈ $86.55 Million |
-32.00% |
| 2022-12-31 | NT$4.04 Billion ≈ $127.28 Million |
-7.43% |
| 2021-12-31 | NT$4.36 Billion ≈ $137.51 Million |
+31.69% |
| 2020-12-31 | NT$3.31 Billion ≈ $104.42 Million |
+31.68% |
| 2019-12-31 | NT$2.52 Billion ≈ $79.30 Million |
+29.25% |
| 2018-12-31 | NT$1.95 Billion ≈ $61.35 Million |
+18.87% |
| 2017-12-31 | NT$1.64 Billion ≈ $51.61 Million |
-- |
About Medeon Biodesign
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular g… Read more